[Adjuvant gestagen therapy of endometrial carcinoma (author's transl)].
Reference is made in this paper to histological findings, with the view to presenting the results of preoperative gestagen therapy, using hydroxyprogesterone capronate, applied to 334 patients with endometrial carcinomas. Complete tumour regression was achieved in 8.7 per cent of these cases. Further differentiation and increased secretion of the tumour cell were recorded in 56.6 per cent. No gestagen effect at all was recordable from 34.7 per cent only.--Sensitivity of endometrial carcinomas to gestagens was at its highest in cases of highly differentiated adenocarcinomas, in premenopausal women, in the presence of oestrogenic colpocytological reaction, and when endometrial carcinomas coincided with adipositas and diabetes mellitus.--Five-year survival rates, following surgery in combination with hormonal therapy, reached 91,3 per cent and thus were in excess of the 78.6 per cent recorded from patients with surgical treatment alone.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D000230:Adenocarcinoma / Q000188:drug therapy; D000328:Adult; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D007044:Hysterectomy; D008875:Middle Aged; D009367:Neoplasm Staging; D045167:Progesterone Congeners / Q000627:therapeutic use*; D011379:Prognosis; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D006908:Hydroxyprogesterones; D045167:Progesterone Congeners; D000077713:17 alpha-Hydroxyprogesterone Caproate
Die adjuvante Gestagentherapie des Endometriumkarzinoms.